Trial Profile
A Pilot Study of Pembrolizumab and Neoadjuvant Radiation for Large, High-Risk Soft Tissue Sarcomas
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 07 Aug 2023 Status changed from active, no longer recruiting to completed.
- 06 Jul 2023 Planned End Date changed from 1 Jan 2024 to 4 Aug 2023.
- 19 Apr 2023 Planned End Date changed from 1 Dec 2023 to 1 Jan 2024.